Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — 40th Annual J.P. Morgan Healthcare Conference 2022
17 slides from Cencora's conference presentation, Jan 10, 2022
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference JANUARY 2022 Steve Collis Chairman, President & CEO
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the "Securities Exchange Act"). Words
Slide 3: AmerisourceBergen: A global healthcare leader
AmerisourceBergen: A global healthcare leader Creating unparalleled access, efficiency, and reliability across the global pharmaceutical supply chain Foundation of leadership Differentiated by complementary New Segments in pharmaceutical distribution higher margin & high growth U.S. Healthcare Solut
Slide 4: U.S. Healthcare Solutions
U.S. Healthcare Solutions Leadership in human and animal health Long-term strategic relationships with key anchor customers across all channels Leadership in specialty distribution & commercialization services differentiates our upstream & downstream value proposition Favorable market trends, includ
Slide 5: International Healthcare Solutions
International Healthcare Solutions Leading global platform offers broad and deep suite of innovative services Leading pan-European wholesaler and related solutions provider Innovative provider of upstream pharma manufacturer services, including a range of key market services and solutions Global spe
Slide 6: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to ESG Why we exist We are united in our responsibility to create healthier futures Our areas of focus Specialty medicine Community providers Cust
Slide 7: Innovative partner providing differentiated solutions
Innovative partner providing differentiated solutions Supporting pharmaceutical innovation in precision medicine, cell and gene, and burgeoning therapies Global specialty logistics, pre-wholesaling and 3PL services Robust cold-chain storage infrastructure and cutting-edge monitoring tools Industry-l
Slide 8: 2021 Highlights
2021 Highlights Strategic • Completed acquisition of Alliance Healthcare and • Facilitated COVID-19 therapy distribution across the U.S. Operational • Supported Strategic National Stockpile • Extended and expanded strategic partnership with Walgreens • Delivered strong FY 2021 financial performance
Slide 9: Investing in our people and culture
Investing in our people and culture Advancing the value of our most important resource • Capture the value of our collective differences by building a culture of equity, inclusion, and belonging • Support strategic success with differentiated learning, development, and growth platforms • Unlock indi
Slide 10: Advancing environmental, social, and governance initiatives to create healthier futures around the world
Advancing environmental, social, and governance initiatives to create healthier futures around the world ENVIRONMENTAL SOCIAL Adapting to a changing climate Investing in our people and • Reduced greenhouse gas emissions by communities over 10.5% in fiscal 2020 from fiscal 2019 • COVID-19 response in
Slide 11: Creating shareholder value
Creating shareholder value Delivering long-term, sustainable growth Adjusted diluted EPS* 10.5% 5-YEAR CAGR $9.26 $7.90 $7.09 $6.49 $5.62 $5.88 FY16 FY17 FY18 FY19 FY20 FY21 11 *See Appendix for GAAP to non-GAAP reconciliation of adjusted diluted EPS.
Slide 12: Appendix
Appendix
Slide 13: Adjusted diluted earnings per share
Adjusted diluted earnings per share Fiscal years ended September 30, 2016, through September 30, 2021 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 GAAP EPS $ 7.39 $ (16.65) $ 4.04 $ 7.53 $ 1.64 $ 6.32 Gains from antitrust litigation settlements (0.58) (0.03) (0.51) (0.12) - (0.35) LIFO (credit) expense
Slide 14: Non-GAAP reconciliation notes
1. Includes a $147.7 million legal expense accrual related to opioid litigation settlements. 2. Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business. 3. Includes $127.6 million of expens
Slide 15: Non-GAAP reconciliation notes
1. Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits. 2. Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business. 3. Represents a tax benefit relating to Swiss tax reform. 15
Slide 16: Non-GAAP reconciliation notes
1. For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP presentation. Note: For more information related to non-GAAP financial measures, refer to
Slide 17: Contact
Might swap. Looks like crack pipe or something Contact Bennett S. Murphy Senior Vice President Investor Relations bmurphy@amerisourcebergen.com
AmerisourceBergen — 40th Annual J.P. Morgan Healthcare Conference 2022 on 6ix